Genmab A/S Announces TEPKINLY Has Received Second European Commission Approval For The Treatment Of Relapsed/Refractory Follicular Lymphoma In Adults
Portfolio Pulse from Benzinga Newsdesk
Genmab A/S has received European Commission approval for TEPKINLY, a subcutaneous bispecific antibody, for treating relapsed/refractory follicular lymphoma in adults. This marks the second approval for TEPKINLY in the EU.
August 19, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab A/S has received conditional marketing authorization from the European Commission for TEPKINLY, a subcutaneous bispecific antibody, for treating relapsed/refractory follicular lymphoma in adults. This approval could enhance Genmab's market position in the EU.
The approval of TEPKINLY by the European Commission is a significant regulatory milestone for Genmab, potentially increasing its market share and revenue in the EU. This is likely to positively impact GMAB's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100